Last updated on: 04/01/2023
1. Contact details
This data source is maintained by the following centre registered in the ENCePP inventory of research centres: PHARMO Institute
Name of data sourcePHARMO Data Network
Name under which the data source should be displayed in the inventory (e.g short name if one exists)PHARMO Data Network
Name of organisation
1) Department/research group
2) Organisation/affiliationThe PHARMO Institute for Drug Outcomes Research
Administrative Contact
Title Ms
Last name van Engeland
First name Heleen
Address line 1Van Deventerlaan 30-40
Address line 2
Address line 3
CityUtrecht
Postcode3528 AE
CountryNetherlands
Scientific Contact
Title Professor
Last name Herings
First name Ron
Address line 1Van Deventerlaan 30-40
Address line 2
Address line 3
CityUtrecht
Postcode3528 AE
CountryNetherlands
2. Description/category
Disease/case registry
Routine primary care electronic patient registry
Pharmacy dispensing database
The PHARMO Data Network is a population-based network of healthcare databases and combines data from different healthcare settings in the Netherlands .These different data sources, including general practitioner, in- and out-patient pharmacy, clinical laboratory, hospitals, cancer registry, pathology registry and perinatal registry, are linked on a patient level through validated algorithms.
3.1 Coverage of licensed medicinal products
Licensed Medicinal Product
Comments
Hospital data
Community / general practice data
3.2 ATC code (5th level)
Yes
3.3 Other product dictionaries
No
3.4 Recording of indication for use
No
4. Coverage of events
Event
Dictionary
Dictionary details
Symptoms/signs
Yes
ICPC
Diagnosis in primary care
Yes
ICPC
Specialist diagnosis
Yes
ICD9/ICD10
Discharge diagnosis
Yes
ICD9/ICD10
Laboratory values
Yes
WCIA
Death
Yes
Date of death
Procedures
Yes
CvV/ZA/CBV
5. Year of establishment
1993
6. Geographical origin of data
EEA/EFTA countries
Netherlands
7. Demographical extent of data collection
Regional sub-set :
The longitudinal nature of the PHARMO Data Network system enables to follow-up more than 10 million persons of a well-defined population in the Netherlands for an average of twelve years. Currently, the PHARMO Data Network covers over 7 million active persons out of 17 million inhabitants of the Netherlands.
8. Age groups
17 years and under [Paediatrics]
preterm newborn infants
term newborn infants (0 to 27 days)
infants and toddlers (28 days to 23 months)
children (2 to 11 years)
adolescents (12 to 17 years)
18 to 45 years
46 to 64 years
65 years and over
65 to 75 years
76 years and over
9. Size of the source/catchment population
7,000,000
10 a. Total (cumulative) number of persons with actual data
10,000,000
10 b. Number of persons with active data collection in past calendar year
7,000,000
11. Possibility to obtain additional information on the patient
a) Clinical information from treating physician?
Yes
b) Questionnaire data from the patient?
Yes
c) Genetic information or samples?
Yes
12. Possibility of links to other sources of data
Yes :
Record Linkage. General practitioner data, in-patient pharmacy data, clinical laboratory data, hospital data, cancer data, pathology data, perinatal data, and others upon request.
13. Written policy governing data access
Yes
14. Committee to evaluate requests for data access
Yes
15. Charge/fee for data access
Yes
Special arrangements for academic purposes:
Yes
16. Selected publications of the last 5 calendar years using data from this data source
ReferenceLink to web-publication
Kuiper JG, Bakker M, Penning-van Beest FJA, Herings RMC. Existing Data Sources for Clinical Epidemiology: The PHARMO Database Network. Clin Epidemiol. 2020 Apr 29;12:415-422.https://pubmed.ncbi.nlm.nih.gov/32425609/
Penning-van Beest FJA, Bezemer ID, Smits E, García Rodríguez LA, Cea Soriano L, Lapi F, Simonetti M, Asiimwe A, Herings RMC. Reduction in use of cyproterone/ethinylestradiol (Diane-35 and generics) after risk minimization measures in the Netherlands, UK and Italy. Contraception. 2020 Oct;102(4):243-245.https://pubmed.ncbi.nlm.nih.gov/32470466/
Heintjes EM, Bezemer ID, Prieto-Alhambra D, Smits E, Booth HP, Dedman D, He Y, Hoti F, Vehkala M, de Vogel S, Robinson NJ, Appenteng K, Penning-van Beest FJA. Evaluating the Effectiveness of an Additional Risk Minimization Measure to Reduce the Risk of Prescribing Mirabegron to Patients with Severe Uncontrolled Hypertension in Four European Countries. Clin Epidemiol. 2020 May 1;12:423-433. https://pubmed.ncbi.nlm.nih.gov/32431551/
Overbeek JA, van Herk-Sukel MPP, Vissers PAJ, van der Heijden AAWA, Bronsveld HK, Herings RMC, Schmidt MK, Nijpels G. Type 2 Diabetes, but Not Insulin (Analog) Treatment, Is Associated With More Advanced Stages of Breast Cancer: A National Linkage of Cancer and Pharmacy Registries. Diabetes Care. 2019 Mar;42(3):434-442. https://pubmed.ncbi.nlm.nih.gov/30679303/
Kuiper JG, van Herk-Sukel MPP, Castellsague J, Pottegård A, Berglind IA, Dedman D, Gutierrez L, Calingaert B, Hallas J, Sundström A, Gallagher AM, Kaye JA, Pardo C, Rothman KJ, Perez-Gutthann S. Use of Topical Tacrolimus and Topical Pimecrolimus in Four European Countries: A Multicentre Database Cohort Study. Drugs Real World Outcomes. 2018 Jun;5(2):109-116. https://pubmed.ncbi.nlm.nih.gov/29736842/
